Journal: Current Drug Metabolism
Guest editor(s):Dr. Ntethelelo Hopewell Sibiya
Co-Guest Editor(s): Andile Khathi,

Introduction

The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced endocrine disorders include disorders of carbohydrate and lipid metabolism, electrolyte handling disturbances and drug-induced thyroid, adrenal, and gonadal disorders. Furthermore, endocrine disorders have been shown to alter drugs pharmacokinetic and pharmacodynamic response, thus affecting the managing other diseases. Studies have indicated altered drug binding, distribution, and elimination in endocrine and metabolic disorders. This thematic issue therefore provides an opportunity to further accelerate our understanding on the interaction between drugs and endocrine disorders. The prevalence of endocrine disorders is increasing at an alarming rate, it is therefore important we expedite our understanding, not only to prevent drug-induced endocrine disorders but also acknowledge the endocrine disorder’s role in the alteration of drugs pharmacokinetic and pharmacodynamic response, as it may affect management of diseases from a clinical perspective. This thematic issue intends to accept and publish high quality commentary, review and original research papers aiming to provide advancement in our understanding on the interaction between drugs and endocrine/metabolic diseases

Keywords

drug-induced, diabetes mellitus, endocrine disorders, metabolic disorders, pharmacokinetics, pharmacodynamic response

Sub-topics

1. Drug-induced glucose handling impairments
2. Dru-induced hepatic and lipid metabolism
3. Altered pharmacokinetic profile in diabetes mellitus and other endocrine/metabolic disorders
4. Altered pharmacodynamic response in diabetes mellitus and other endocrine/metabolic disorders
5. Pharmacological management of other diseases in diabetics: Clinical perspective